Clinical trials: Single Embryo Transfer/Double Embryo Transfer
- Condition Single Embryo Transfer/Double Embryo Transfer
- Funder type Industry (pharma, biotech, devices)
Infertility, Female, Infertility
Phase II Clinical Trial to Evaluate the Ongoing Pregnancy Rate With OXO-001 in IVF/ICSI With Donor Oocytes.
The main objective of this clinical research trial is to test the efficacy of OXO-001 in a daily oral administration increasing the pregnancy rate in IVF/ICSI by preparing the uterus to receive the embryo.
- Trial name
- OXOART2 (NCT05076032)
- Testing
- OXO-001
- Where
- 28 sites in Czechia, Poland and 1 more
- Volunteers
- 408 people
- Sponsor
- OXOLIFE
Infertility
Subcutaneous Progesterone in Frozen- Thawed Single Euploid Blastocyst Transfer.
This is a multicenter, randomized, double-blind, double-dummy, active-controlled, non-inferiority clinical study in women aged 35 to 42 years.
- Trial name
- PROGRESS (NCT04549116)
- Testing
- Progesterone-IBSA Injectable Solution, Progesterone Vaginal Gel with Applicator
- Where
- 24 sites in United States
- Volunteers
- 688 people
- Sponsor
- IBSA Institut Biochimique SA
Infertility
OBE001 Phase 2 Dose-finding Study Versus Placebo in Women Undergoing Embryo Transfer in the Context of IVF-ICSI
The primary objective of this study is to assess the increase in clinical pregnancy rate after administration of a range of single oral doses of OBE001, an oral oxytocin antagonist, compared to placebo.
- Trial name
- IMPLANT (NCT02310802)
- Testing
- OBE001 dose 1, OBE001 dose 2, OBE001 dose 3
- Where
- 18 sites in Belgium, Czechia and 4 more
- Volunteers
- 247 people
- Sponsor
- ObsEva SA
Amyotrophic Lateral Sclerosis
GM604 Phase 2A Randomized Double-blind Placebo Controlled Pilot Trial in Amyotrophic Lateral Disease (ALS)
GM604 is an endogenous human embryonic stage neural regulatory and signaling peptide that controls the development, monitoring and correction of the human nervous system.
- Trial name
- GALS (NCT01854294)
- Testing
- GM604
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Genervon Biopharmaceuticals, LLC
Infertility
Phase 3 Placebo Controlled Study of Nolasiban to Improve Pregnancy Rates in Women Undergoing IVF/ICSI
The primary objective of this study is to confirm the efficacy of a single oral 900mg dose of nolasiban to increase the ongoing clinical pregnancy rate at 10 weeks post embryo transfer (ET) day.
- Trial name
- IMPLANT2 (NCT03081208)
- Testing
- Nolasiban 900mg
- Where
- 43 sites in Belgium, Czechia and 7 more
- Volunteers
- 810 people
- Sponsor
- ObsEva SA